The startup develops antibody immunotherapies targeting resistance to covalent inhibitors of oncoproteins, specifically designed to halt the progression of aggressive cancers. This approach enables oncologists to offer effective treatment options for patients facing limited therapeutic alternatives.
Funding
Funding not disclosed
Founders
Product
Problem
Covalent inhibitors of oncoproteins show promise in cancer treatment, but resistance mechanisms often emerge, limiting their long-term effectiveness. This resistance leaves patients with aggressive cancers facing limited therapeutic options and disease progression.
Solution
The startup develops antibody immunotherapies specifically designed to overcome resistance to covalent inhibitors of oncoproteins. These immunotherapies target the mechanisms that cancer cells use to evade the effects of covalent inhibitors, thereby restoring the drug's efficacy and halting cancer progression. By addressing the root cause of resistance, the startup aims to provide oncologists with more effective treatment options for patients with aggressive cancers who have exhausted other therapeutic avenues. This approach seeks to extend the duration of response to covalent inhibitors and improve patient outcomes.
Target Audience
The primary target audience includes oncologists treating patients with aggressive cancers who have developed resistance to covalent inhibitors, as well as patients who have exhausted other treatment options.
Features
- Antibody-based immunotherapies targeting specific resistance mechanisms to covalent inhibitors
- Designed to restore the efficacy of covalent inhibitors in resistant cancer cells
- Focus on aggressive cancers with limited therapeutic alternatives